Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flt3 Ligand in AML Patients in Remission
NCT00006223Phase 3Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Jul 2000
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute myeloid leukemia (AML) comparing Flt3 Ligand with Observation (2 arms). Primary endpoints: Failure-Free Survival and Overall Survival. Started Jul 2000; status: completed.
02
Drugs
Flt3 ligand
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00006223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006223.